BridgeMD
New treatment option for Multiple Sclerosis
Official title Non-invasive Brain Stimulation in Multiple Sclerosis Fatigue
ClinicalTrials.gov ID: NCT07438964
What this study is testing
- What it's testing
- The neurobiological basis of central fatigue in multiple sclerosis remained unclear so far. This study investigates reward-related brain mechanisms, inflammation, and their modulation by non-invasive brain stimulation using fMRI, proteomics, and clinical measures to improve future treatment of central fatigue in MS.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Men and women
- 18 - 70 years
- Established MS diagnosis (relapsing-remitting MS; RRMS) prior to study inclusion
- Maximal EDSS of 4
- Maximal disease duration 10 years
You likely can't join if
- MRI contraindications
- Known endocrine, immunologic, psychiatric, and neurologic disease (other than RRMS and Major Depressive Diosorder)
- Current treatment with pharmaceuticals affecting monoaminergic functioning such as Levodopa, Amantadin, Fluoxetin, Paroxetin or antipsychotics
- Relapse or treatment with steroids in last four weeks window prior to study onset
- DMT other than B-cell depleting monoclonal antibodies or fumarates
- Sleep disorder as assessed with Pittsburgh Sleep Quality Index
See the full eligibility criteria
- Men and women
- 18 - 70 years
- Established MS diagnosis (relapsing-remitting MS; RRMS) prior to study inclusion
- Maximal EDSS of 4
- Maximal disease duration 10 years
- Existing health insurance
- Stable or no treatment with disease modifying treatment (DMT) in last six months prior to study onset
- Persons with RRMS and FSMC score ≥ 22 will be included in group "RRMS with fatigue"
- Persons with RRMS and FSMC score \< 22 will be included in group "RRMS without fatigue"
- MRI contraindications
- Known endocrine, immunologic, psychiatric, and neurologic disease (other than RRMS and Major Depressive Diosorder)
- Current treatment with pharmaceuticals affecting monoaminergic functioning such as Levodopa, Amantadin, Fluoxetin, Paroxetin or antipsychotics
- Relapse or treatment with steroids in last four weeks window prior to study onset
- DMT other than B-cell depleting monoclonal antibodies or fumarates
- Sleep disorder as assessed with Pittsburgh Sleep Quality Index
The study team makes the final eligibility decision.
Where it's taking place
- Berlin, State of Berlin, Germany
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Berlin, State of Berlin, Germany. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.